| Code | 4425D | ||||||||||
| MA number | EU/1/20/1431/002 | ||||||||||
| Product Form: | con inf 1x50 ml/500 mg (liek.inj.skl.) | ||||||||||
| MA Status: | E - Valid centralised marketing authorisation | ||||||||||
| Type of procedure: | EU | ||||||||||
| MAH, country: | Pfizer Europe MA EEIG, Belgium | ||||||||||
| Therapeutic Class: | 59 - IMMUNOPRAEPARATA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 24 | ||||||||||
| Container: | glass vial | ||||||||||
| Route of admin.: | Intravenous use |
| Prescription Status: | Medicinal product subject to restricted medical prescription. |
| Legal basis: | Article 10(4) similar biological application |
| MA issued: | 01.04.2020 |
| SmPC + PL: |
European Medicines Agency's database
|
| Dokument: |
rituximab_Karta_pacienta.pdf
|
| Safety feature | Yes |
| Data update: | 02.01.2025 |
